Project Grant R01CA301721
Award Date
4/8/25
Completion Date
3/31/28
Dollars Obligated
$768K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) totaling $542,663 will fund research at the University of Texas MD Anderson Cancer Center aimed at developing novel targeted therapies for acute myeloid leukemia (AML) with MLL rearrangement or mutant NPM1. The overarching research objectives are to evaluate the preclinical efficacy of BRG1/BRM antagonists as monotherapies and in combination with standard and investigational agents, as well as...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides funding to the Beckman Research Institute of the City of Hope to investigate the role, mechanism, and therapeutic potential of the RNA methyltransferase METTL1 in acute myeloid leukemia (AML). The key objectives are to: 1) further consolidate the importance of METTL1 function in AML using mouse models, 2) understand the role of the METTL1/tRNAPheGAA/HCK signaling axis in leukemia stem...
This $1,398,552 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports advanced preclinical research by Avantgen Inc., a San Diego-based biotechnology company, to develop a novel antibody therapy targeting the Jagged-1 pathway for treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The grant funding will enable Avantgen to conduct preliminary Investigational New Drug (IND)-enabling studies, including...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $185,831 to the University of Pittsburgh for a 2-year research project to discover and develop allosteric inhibitors of the Src-family kinases HCK and FGR for the treatment of acute myeloid leukemia (AML). The goals are to: 1) synthesize and test analogs of existing allosteric modulators for the AML-associated kinase HCK, and 2) identify additional scaffolds for allosteric regulation of...
This federal Project Grant award for $476,558, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), aims to develop novel inhibitors and proteolysis targeting chimeras (PROTACs) targeting the ENL protein as potential therapeutics for acute myeloid leukemia (AML). The principal investigator's team at Texas A&M University will pursue three primary objectives: 1) Develop more potent, stable, and selective small molecule ENL inhibitors and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Sanford Burnham Prebys Medical Discovery Institute to discover potent and selective inhibitors of the histone methyltransferase SUV39H1 for the treatment of cancer. With $809,234 in total funding from July 1, 2024 to June 30, 2029, the research aims to identify SUV39H1 inhibitor scaffolds through high-throughput screening, optimize lead compounds, and evaluate their...
This $441,178 Project Grant award, funded by the National Cancer Institute under the Cancer Biology Research (CFDA 93.396) program, supports research to overcome therapy resistance in fusion oncoprotein-driven pediatric leukemia. The Icahn School of Medicine at Mount Sinai (ISMMS) leads this 5-year effort to investigate the developmental dependency and therapeutic vulnerabilities of the NUP98-NSD1 fusion oncoprotein and associated WT1 mutations in acute myeloid leukemia (AML). The research...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $402,600 to the Sloan-Kettering Institute for Cancer Research in New York to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The key objectives are to (1) evaluate the efficacy and safety of U5 snRNP200-targeted CAR T cells,...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $192,240 to the Van Andel Research Institute (VAI) in Grand Rapids, Michigan to conduct research on acute leukemia. The award period runs from June 1, 2024 to May 31, 2027. The key objectives of the research project are to: 1) address how the KMT2A oncoprotein contributes to B-cell acute lymphoblastic leukemia (B-ALL) converting to an acute myeloid leukemia (AML) phenotype, and...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $483,760 to The Trustees of the University of Pennsylvania to conduct research on the role of the DCAF15 protein in acute myeloid leukemia (AML). The primary objectives are to: (A) investigate the biological function of DCAF15 in myeloid development and leukemia in vivo, (B) explore the role of cohesin acetylation in AML pathogenesis, and (C) develop small molecule degraders targeting...